Kiniksa Pharmaceuticals International (KNSA) EV to EBITDA (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported EV to EBITDA for 9 consecutive years, with 347.52 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA rose 90.61% year-over-year to 347.52; the trailing twelve-month figure through Jun 2026 stood at 94.27 (down 88.52% YoY), and the FY2025 full-year result was 76.28, up 232.29% from the prior year.
• EV to EBITDA climbed to 347.52 in Q2 2026 per KNSA's latest filing, from 236.75 in the prior quarter.
• Across five years, EV to EBITDA topped out at 28001.18 in Q4 2023 and bottomed at 19820.35 in Q2 2024.
• Historically, EV to EBITDA has averaged 468.7 across 5 years, with a median of 9.33 in 2022.
• The sharpest annual moves came in 2023 and 2024: EV to EBITDA soared 8819.43% in 2023, then plunged 3537.68% in 2024.
• Over 5 years, EV to EBITDA stood at 313.93 in 2022, then jumped by 8819.43% to 28001.18 in 2023, then slumped by 100.49% to 136.29 in 2024, then surged by 318.63% to 297.96 in 2025, then rose by 16.63% to 347.52 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 347.52, 236.75, and 297.96 for Q2 2026, Q1 2026, and Q4 2025 respectively.